Abstract 17P
Background
Breast cancer is the most common cancer in women in Poland. In patients with cancer located on the left side, breast radiotherapy is associated with the irradiation of part of the heart. It was calculated that for every 1 Gy dose of radiation deposited in the heart, the risk of heart complications increases by 7.4%.
Methods
The subject of analysis was a group of 50 patients treated in the National Institute of Oncology, Department of Radiotherapy, Gliwice from June 2018 to December 2019. The age of patients ranged from 30 to 70 (median 63 years). All patients were after surgeries (38 patients after BCT with SNB and 12 patients after left breast amputation). All patients were additionally irradiated using Deep Inspiratory Breath Hold technique. Dose distributions per heart and lungs were compared in IMRT, Rapid Arc, and DIBH techniques. Radiation complications from the skin were assessed according to WHO scale.
Results
In all irradiated patients the dose distribution in the technique on suspended inhalation was better compared to the dynamic IMRT and Rapid Arc techniques, with dose reduction per heart by about 10-15% and per lung from 5 to 10%. No higher than II degree of acute and late skin reaction in the DIBH technique was observed in comparison with dynamic techniques.
Conclusions
1) Deep Inspiratory Breath Hold technique is a simple non-invasive method which effectively reduces the dose of radiation absorbed by the heart muscle. 2) Irradiation of patients with deep inspiratory allows a reduction of the lungs dose by about 5-10 %. 3) The technique of irradiation of patients during deep inspiratory is a simple, non-invasive method of treatment of patients reducing the risk of radiation complications from the heart and the lungs in comparison with dynamic, IMRT, and Rapid Arc techniques.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors” without further recourse to the authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
372P - Treatment patterns and outcomes in stage III non-small cell lung cancer (NSCLC): Real-world experience in Singapore from the KINDLE study
Presenter: Ross A. Soo
Session: e-Poster Display Session
373P - Chromatin accessibility reveals potential prognostic value of the peak set associated with smoking history in patients with lung adenocarcinoma
Presenter: Jianlian Deng
Session: e-Poster Display Session
384P - BLU-945, a highly potent and selective 4th generation EGFR TKI for the treatment of EGFR T790M/C797S resistant NSCLC
Presenter: Stefanie Schalm
Session: e-Poster Display Session
385P - Patient reported outcomes (PROs) analysis for patients with ROS1 fusion-positive (ROS1+) non-small cell lung cancer (NSCLC) receiving entrectinib in the global phase II STARTRK-2 study
Presenter: Fabrice Barlesi
Session: e-Poster Display Session
386P - A single-arm phase Ib study of autologous cytokine-induced killer (CIK) cell immunotherapy in combination with sintilimab plus chemotherapy in patients with advanced non-small cell lung cancer (NSCLC)
Presenter: LI Zhou
Session: e-Poster Display Session
387P - Phase Ib study of savolitinib ± osimertinib in Japanese patients (pts) with advanced solid malignancies & EGFRm NSCLC: TATTON part C
Presenter: Tomonori Hirashima
Session: e-Poster Display Session
388P - Biosimilar TAB008 compared with bevacizumab in advanced non-squamous, non-small cell, EGFR wildtype lung cancer patients
Presenter: Zhen Zhou
Session: e-Poster Display Session
389P - Updated analysis from the KEYNOTE-042 China study: 1L pembrolizumab (pembro) vs chemotherapy (chemo) in Chinese patients (pts) with advanced NSCLC with PD-L1 TPS ≥1%
Presenter: Yi-Long Wu
Session: e-Poster Display Session
391P - Economic impact of next-generation sequencing (NGS) versus single-gene testing modalities to detect genomic alterations (GAs) in metastatic non-small cell lung cancer (mNSCLC) in Asia
Presenter: Herbert Loong
Session: e-Poster Display Session
392P - Clinical data from the real world: Efficacy analysis of ceritinib (450mg) in ALK-positive non-small cell lung cancer patients with brain metastases in China
Presenter: Zhixin Qiu
Session: e-Poster Display Session